Speech-Language Pathologists in Berwyn, PA Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Lindsay Stotts, MS, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 511 Old Lancaster Rd Ste 12, Berwyn, PA 19312 Phone: 610-225-2451    Fax: 610-964-6166

Lindsay Bly, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2600 Wayland Rd, Berwyn, PA 19312 Phone: 610-325-4987

Mrs. Kristen C Binkley, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 716 Hillside Ave, Berwyn, PA 19312 Phone: 201-321-3483

Richard Fontanet Jr. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 91 Central Ave Apt A, Berwyn, PA 19312 Phone: 954-646-6482

Leah Patricia Burns, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 321 Greene Rd, Berwyn, PA 19312 Phone: 610-296-2672

Kathryn Bruni, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Carol Ln, Berwyn, PA 19312 Phone: 610-755-2548

Mrs. Barbara Baker Dougherty, SPEECH LANGUAGE PATH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 850 Old State Rd, Berwyn, PA 19312 Phone: 610-296-9768

Ms. Adrianne Catherine Pepitone, M.A., CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 196 Daylesford Blvd, Berwyn, PA 19312 Phone: 484-802-4671

News Archive

Emerging protein-based immunotherapies could lead to highly effective cancer treatments

In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective "off-the-shelf" cancer treatments for more patients.

Stimulus funds boost Utah health IT pipeline

Utah's health department will use $6.3 million in federal dollars to build a "computer pipeline" that will allow doctors and hospitals to share patient information, The Salt Lake Tribune reports.

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

A team of investigators at Rational Therapeutics, Inc. and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

SILADENT and Innodema appointed as SensAble Authorized Production Centers

SensAble Technologies Inc., a leading provider of dental restoration design and fabrication solutions, 3D modeling software and haptic devices, announced that it has further expanded its network of European partners in service to the growing dental lab business in Europe. The company today announced partnerships with SILADENT Dr. Böhme & Schöps GmbH, Goslar, German and Innodema, an alliance of dental lab fabrication experts based in Belgium, both of whom become SensAble Authorized Production Centers (SAPCs).

Read more Medical News

› Verified 3 days ago